2 completed, 2 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Terminated 2 |
Follow lonafarnib: new trials by email Literature Review of lonafarnib trials Research Report on lonafarnib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection Lonafarnib, Ritonavir - Hepatitis D, Chronic | Phase 3 | Completed | Soroka University Medical Center | 10 | 2021-05-15 | 2026-04-30 |
| Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Lonafarnib, Ritonavir, PEG IFN-alfa-2a - Hepatitis Delta Virus | Phase 3 | Completed | Eiger BioPharmaceuticals | 407 | 2018-12-01 | 2023-04-14 |
| Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Lonafarnib, Placebo - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 47 | 2005-05-01 | 2015-05-01 |
| Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) Lonafarnib (SARASAR) - Carcinoma, Non-small-cell Lung, Metastases, Neoplasm | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 702 | 2002-12-01 | 2015-08-27 |
Hepatitis D (2) · Anemia, Refractory, with Excess of Blasts (1) · Carcinoma, Non-Small-Cell Lung (1) · Hepatitis B (1) · Hepatitis D, Chronic (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1)
Merck Sharp & Dohme LLC (2) · Eiger BioPharmaceuticals (1) · Soroka University Medical Center (1)
Israel (2) · New Zealand (2) · Turkey (Türkiye) (2) · Belgium (1) · Bulgaria (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Moldova (1) · Mongolia (1) · Pakistan (1) · Romania (1) · Russia (1)
Ohad Etzion, MD (1)